EP3515215B1 - Mittel zur modulation der sensorischen auswirkung von tabak- oder pflanzlichem rauch - Google Patents

Mittel zur modulation der sensorischen auswirkung von tabak- oder pflanzlichem rauch Download PDF

Info

Publication number
EP3515215B1
EP3515215B1 EP17854026.6A EP17854026A EP3515215B1 EP 3515215 B1 EP3515215 B1 EP 3515215B1 EP 17854026 A EP17854026 A EP 17854026A EP 3515215 B1 EP3515215 B1 EP 3515215B1
Authority
EP
European Patent Office
Prior art keywords
tobacco
agent
channel
tobacco substitute
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17854026.6A
Other languages
English (en)
French (fr)
Other versions
EP3515215A4 (de
EP3515215A1 (de
Inventor
Reid Von Borstel
Dennis Tan
John SIVERLING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1sourceit LLC
Original Assignee
SENTIENS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SENTIENS LLC filed Critical SENTIENS LLC
Publication of EP3515215A1 publication Critical patent/EP3515215A1/de
Publication of EP3515215A4 publication Critical patent/EP3515215A4/de
Application granted granted Critical
Publication of EP3515215B1 publication Critical patent/EP3515215B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F47/00—Smokers' requisites not otherwise provided for
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/281—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed
    • A24B15/283—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed by encapsulation of the chemical substances
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/302—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by natural substances obtained from animals or plants
    • A24B15/303—Plant extracts other than tobacco

Definitions

  • Tobacco smoke is a causal risk factor for cancer (especially but not exclusively lung cancer), cardiovascular disease, and lung dysfunction, including chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • One attempted strategy has been to produce cigarettes with low tar and nicotine delivery during smoking, intended to be below the threshold for establishment or maintenance of nicotine addiction.
  • Such "light” cigarettes have had little impact on smoking-related illnesses, in part due to low consumer satisfaction, but also because smokers tend to compensate for low nicotine, tar, and flavor component delivery by increasing the number and volume of puffs per cigarette, to titrate nicotine delivery or airway sensations to a level that provides relief from acute tobacco craving symptoms.
  • Another attempted strategy has been to develop methods for nicotine delivery without combustion of tobacco, including "heat-not-burn” technology that seeks to release nicotine from the tobacco via volatilization or formation of an aerosol without many of the toxicants in combusted tobacco smoke, but which still delivers the highly addictive drug nicotine.
  • Smoking remains one of the leading causes of preventable morbidity and mortality throughout the world.
  • the World Health Organization estimates there are around 1.3 billion tobacco users world-wide, and notes that tobacco use causes nearly 6 million deaths per year, with an estimated 8 million deaths a year by 2030, should current trends continue.
  • the Centers for Disease Control and Prevention has stated that smoking is the leading cause of preventable death in the U.S., where there are an estimated 540,000 premature deaths per year due to cigarette smoking, and the economic cost of smoking is estimated to exceed 300 billion per year.
  • new approaches are needed to substitute for the rewarding effects of smoking using less harmful alternatives.
  • EP 2 862 454 A1 discloses an invention relating to a liquid composition for an electronic cigarette, comprising a TRP modulator and at least one TRP agonist / activator, wherein the interaction of the modulator and the at least one agonist / activator results in a chemosensory imitation of inhaled cigarette smoke, and wherein the liquid composition does not contain nicotine.
  • the invention further relates to a use of a modulator and at least one TRP agonist / activator in a liquid composition for electronic cigarettes which does not contain nicotine for inhaling cigarette smoke.
  • US 2014/271733 A1 discloses pharmaceutical compositions and methods of use therefor for reducing the desire to engage in smoking. More specifically, the pharmaceutical composition utilizes an active ingredient to reduce the side effects of smoking cessation and to limit the molecular feedback caused by nicotine-mediated activation of acetylcholine receptors.
  • US 2012/027693 A1 discloses methods and compositions directed to the treatment or amelioration of muscle cramps using a composition that includes one or more TRPV1 channel activators, and/or one or more TRPA1 channel activators, and/or one or more ASIC channel activators
  • WO 2015/091792 Aldiscloses a smoking article having an aerosol generating substrate and a mouthpiece.
  • the mouthpiece includes a cavity at least partially filled with a particulate material, such as activated carbon,and contains at least one breakable capsule of a liquid flavourant at least partially surrounded by the particulate material, such that the force required to break the capsule within the mouthpiece to release the liquid flavourant is less than three times the inherent burst strength of the capsule.
  • US 2009/277465 A1 discloses an improved delivery of additive materials to cigarettes through the use of one or more capsules containing additive materials, such as flavor components, in the filter section of a cigarette.
  • the sealed capsule or capsules are subjected to an external force, such as squeezing, by a smoker prior to or during smoking of the cigarette in order to release at least a portion of the additive material from the one or more capsules and expose the additive material to mainstream smoke passing through the filter.
  • the sealed capsules provide a barrier between the additive materials and other cigarettes components, such as sorbents or filter materials, in order to reduce additive material migration into the other cigarette components prior to desired use.
  • US 2006/144412 A1 discloses an iimproved delivery of additives through encapsulation.
  • the encapsulated additives can be formed by encapsulating additives using co-ionic cross-linking, in-situ overcoating, and/or step-growth overcoating.
  • additives can be made heat and moisture stable and migration and/or loss of the additives within a cigarette, such as an activated carbon containing cigarette, can be reduced.
  • GB 1 284 151 A discloses minute capsules of 50-500 microns diameter containing a volatile flavouring material, for incorporation in tobacco compositions (see Division A2), have rigid walls which are heat rupturable with a crackling sound and may be made from gelatine-gum arabic or gelatinecarrageenan complexes, phased out succinylated gelatines, or ethyl cellulose.
  • a synthetic clove oil is encapsulated in a gelatine-gum arabic complex by first dispersing the oil in a hot solution of gelatine or gum arabic and then stirring in a hot solution of gum arabic or gelatine respectively and cooling the mixture with continued stirring, or by adding the oil to a hot stirred mixture of precipitated gelatine in gum arabic solution (produced by mixing hot solutions of each) and subsequently cooling with continued stirring.
  • Glutyraldehyde is added in some of the examples to harden the formed capsules, and in one example sodium benzoate is also added.
  • the novel cigarette utilizes an irritant selected from the group consisting of one or more constituents from black and/or red pepper, capsaicinoids, and mixtures of the foregoing in the tobacco thereof. Subsequent to igniting the tobacco and inhaling from the cigarette, the irritant creates respiratory tract sensations in a user substantively similar to those obtained by inhalation of tobacco smoke from a conventional cigarette.
  • US 2013/152956 A1 discloses a device for simulating a chemosensation of smoking including an outer layer, a porous medium and a chemesthetic agent.
  • the porous medium is disposed within the outer layer.
  • the chemesthetic agent is disposed within the porous medium and activates a TRP channel.
  • a device includes a wrapper, tobacco disposed in the wrapper, and a first agent that activates a TRPA1 channel disposed in the wrapper.
  • the first agent includes at least one of grains of paradise (Aframomum melegueta), galangal and 6-paradol.
  • the device may be at least partially combustible.
  • the device may include a filter disposed toward an end of the device and coupled to the wrapper.
  • the device may include a capsule operable to be broken by finger pressure.
  • the first agent is disposed in the tobacco, and a second agent that activates at least one of a TRPM8 channel, a TRPV3 channel, and a TRPV1 channel is disposed in the capsule.
  • the second agent may activate the TRPM8 channel and be operable to provide a cooling sensation.
  • the second agent may include at least one of menthol, physcool (monomenthyl succinate), icilin, geraniol, linalool, hydroxycitronellal, WS-3, WS-23, PMD38, Cool-actP, FrescolatMGA, FrescolatMA and PMD38.
  • the device may include a second agent that activates a TRPV3 channel and is operable to provide a warming sensation.
  • the device may include a second agent that activates the TRPV1 channel.
  • the tobacco may be a low nicotine tobacco.
  • the device may include at least one of herb and tea leaves.
  • a device in another example, includes a wrapper, at least one of herb and tea leaves disposed in the wrapper, and a first agent that activates a TRPA1 channel disposed in the wrapper.
  • the device may include a capsule operable to be broken by finger pressure.
  • the first agent may be disposed in the at least one of herb and tea leaves.
  • a second agent that activates at least one of a TRPM8 channel, a TRPV3 channel, and a TRPV1 channel is disposed in the capsule.
  • the second agent may activate the TRPV1 channel.
  • Cigarette smoke constituents including but not limited to nicotine, act on sensory and autonomic afferent nerve terminals sending sensory information to the brain from the mouth, throat and respiratory tract via the vagus, trigeminal and other cranial nerves, and induce autonomic reflexes and effects in the central nervous system that contribute to the subjective experience of cigarette smoking, including "throat scratch,” and to relief of craving, and also to subjective reflex-mediated experiences such as "head rush.”
  • Cigarette smoking causes EEG changes and corresponding subjective experiences in the brain via sensory reflexes even before nicotine is absorbed and transported to the brain.
  • Such sensations in the oral and nasal cavities are mediated via the trigeminal nerve, and are elements of the somatosensory system, distinguishing them from olfaction and taste, although chemesthesis is an integral component of characteristic sensory information about foods or airborne chemicals.
  • chemesthetic signals are transmitted to the brain via the glossopharyngeal and vagus nerves. Chemesthetic signals can thereby directly affect brain activity in the somatosensory cortex and other brain regions, including appetitive circuits involved in craving for particular foods or other chemesthetic stimuli including tobacco smoke.
  • Crossover of chemesthetic signaling provided by compounds of the present disclosure with chemesthetic signaling pathways involved in perception and physiological responses to tobacco smoke contributes to the ability of devices and compositions of the present disclosure to reduce craving or negative affect or mood associated with delay or withdrawal of tobacco smoke.
  • chemosensory signals from the respiratory tract inform the brain that smoke, likely containing nicotine based on experience, has been inhaled, thereby triggering alterations of activity in appetitive circuits involved in converting absence of central nicotinic receptor activation into negative affect or dysphoria associated with cigarette craving.
  • Activation of chemosensory neurons that anatomically or functionally overlap with neurons terminating in the airways that respond to nicotine and other smoke constituents provides signals to the brain that similarly trigger neural reflex-mediated relief of nicotine-withdrawal dysphoria without actually delivering nicotine or potentially toxic smoke constituents resulting from combustion of tobacco.
  • mimicry of tactile, kinesthetic, organoleptic aspects of cigarette smoking in addition to chemosensory mimicry, reinforces the ability of devices and compositions of the present disclosure to relieve symptoms of nicotine withdrawal or cigarette craving.
  • TRP activation can provide warning of potentially noxious environmental or dietary factors
  • TRP stimulation can also elicit pleasure or satisfaction, as is implied by the examples of common TRP activators above.
  • a feature of TRP activation is that chemesthetic sensations (or TRP sensations), which are generally more sensitive to temperature sensations than to smell sensations provide less inherent discrimination between different agonists than is the case for olfactory sensation.
  • Sensory nerve endings associated with the trigeminal, glossopharyngeal and vagus nerves may contain multiple types of chemosensory receptors, providing a basis for chemesthetic mimicry by chemically diverse agents.
  • TRP channels can be activated by concentrations of compounds below those that cause actual physical changes in the respiratory tract, acting as sensitive sentinels of possible irritation or damage. TRP channel activators therefore provide a potential mode of action for volatile constituents to have smoke-mimetic chemosensory or chemesthetic effects without delivery of otherwise bioactive quantities of the sensory agents into the body.
  • an exemplary cigarette device 10 may be approximately the size and shape of a conventional cigarette. Volatile constituents are dispersed within a matrix 12 encased within a wrapper 14 resembling the outer wrap of a conventional cigarette.
  • the wrapper is relatively nonporous, liquid impermeable wrapper 14.
  • the matrix 12 may be provided by a porous material such as cellulose or it may also be provided by tobacco or tobacco substitute product.
  • the end 16 of the device 10 may be constructed to resemble a conventional filter rod in appearance and/or feel. In some embodiments, a filter rod is used at the end 16 of the device 10.
  • the present disclosure is not restricted to cigarette-like devices, but also includes substitute cigars, pipes, e-cigarettes, inhalers, and other devices used to smoke tobacco or mimic smoking.
  • an exemplary embodiment of a device 10 includes a substrate 122 enclosed in a wrapper 123 resembling the outer wrap of a cigarette.
  • the substrate 122 may include a channel 124.
  • the channel 124 may include a tobacco or substitute tobacco product 126 and a porous substrate 128 to contain constituents described herein.
  • the substrate 128 may also be omitted and the constituents applied directly to the tobacco or tobacco substitute product.
  • the tobacco or substitute tobacco product 126 may be separated from the substrate 128 by a substantially non-porous or liquid impermeable barrier to provide separation between the tobacco or substitute tobacco product and the constituents of the disclosure. This may protect the constituents from the heat of burning the tobacco or substitute tobacco product.
  • An untreated region 130 may be included at a second end 132 of the device 10, which is subjected to mouth-applied suction by a user.
  • the untreated region 130 may be untreated cellulose or other filtering material.
  • the untreated region 130 may be a filter plug.
  • the untreated region 130 may be a cellulose acetate tip with a micro capsule (discussed in more detail with respect to Fig. 3 ).
  • the region 130 and part of the channel 124 may be covered with a wrap 134.
  • the wrap 134 enhances visual similarity between the device 10 and a cigarette.
  • the substrate 128 may be disposed inside the region of the device 10 covered by the wrap 134.
  • a portion 136 of the wrap 134 may include trade dress for identifying the device 10 or the maker thereof.
  • the device 10 may have a length of approximately 100 mm and a diameter of approximately 7.9 mm in diameter.
  • the channel 124 may be approximately 80 mm in length and the region 130 may be approximately 20 mm in length.
  • the substrate 128 may be 10 mm or more in length.
  • the wrap 134 may be approximately 30 mm in length.
  • the region 130a is an exemplary cellulose acetate tip with a pellet or capsule 140, such as a micro bead, that is stable and does not release the active agents therein until crushed or broken by finger pressure.
  • the micro capsule 140 may be of various sizes such as 3.5-5mm in diameter.
  • the micro capsule 140 may be arranged with its center at approximately 15 mm from the second end 132.
  • the present disclosure provides a selection of volatile activators of TRP channels and acid sensitive ion channels which, when incorporated into a low nicotine or non-nicotine combustion or heating device, provide improved chemosensory mimicry of the experience of nicotine delivery versus prior low nicotine or non-nicotine delivery devices.
  • the compositions of this disclosure may impart chemosensory activity without also providing undesirable flavors.
  • compositions of the disclosure include ingredients that are co-delivered with tobacco or botanical tobacco substitute smoke, or with vapor from tobacco or botanical tobacco substitute materials.
  • tobacco or botanical tobacco substitute smoke or with vapor from tobacco or botanical tobacco substitute materials.
  • filter elements are optionally pellets or capsules that are stable and do not release the active agents until crushed or broken by finger pressure, or by incorporating segmented filter technology to embed a section to co-deliver ingredients.
  • Agents of the disclosure for simulating or amplifying throat or airway sensations associated with cigarette and herbal smoking or aerosolizing include sensate constituents of aframomum malagueta, including 6-paradol, of galangal root, including galangal acetate and its analogs, of hydroxy-alpha sanshool which is found in extracts of Szechuan peppers, of thymol which is found in extracts of Thyme, and of camphor and its analogs which is found in extracts of rosemary.
  • 6-paradol or galangal is combined in a cigarette, which may include the tobacco or botanical tobacco substitute, with an agent that provides a cooling effect by acting on TRPM8, a transient receptor potential channel mediating a cooling sensation evoked by agonists, including but not limited to menthol, physcool (monomenthyl succinate), icilin, geraniol, linalool, hydroxycitronellal, WS-3, WS-23, PMD38, Cool-actP, FrescolatMGA, FrescolatMA and PMD38.
  • the cooling agent is optionally added to the tobacco and is delivered by combustion or volatilization in a heat-not-burn device.
  • the cooling agent is incorporated into the cigarette filter, either by application to the filter itself, or by encapsulation in a crushable pellet or capsule that releases volatile cooling agent into mainstream smoke when broken by finger pressure.
  • 6-paradol or galangal is combined in a cigarette, which may include the tobacco or botanical tobacco substitute, with agents that provide an additional trigeminal sensory effect by acting on TRPA1 and TRPV1, transient receptor potential channels evoked by agonists, including but not limited to hydroxy-alpha sanshool which is found in extracts of Szechuan peppers, isothiocyanates which are found in extracts of Mustard Seed, Yellow Mustard, or combinations thereof.
  • the TRPV1 and TRPA1 agonists are optionally incorporated into the tobacco, as either a purified or semi-purified compound, a semi-purified extract, or as a simple ethanolic or methanolic extract of a botanical material of which the TRPV1 and TRPA1 agent is an endogenous constituent.
  • 6-paradol or galangal is combined in a cigarette, which may include the tobacco or botanical tobacco substitute, with an agent that provides an additional trigeminal sensory effect by acting on TRPV3, a transient receptor potential channel mediating a warming sensation evoked by agonists, including but not limited to carvacrol, thymol, eugenol, eucalyptol, incensol, borneol, camphor, dihydrocarveol or combinations thereof.
  • the TRPV3 agonist is optionally incorporated into the tobacco or herbal cut rag, as either a purified or semi-purified compound, a semi-purified extract, or as a simple ethanolic extract of a botanical material of which the TRPV3 agent is an endogenous constituent.
  • the TRPV1 and/or TRPV3 agents are incorporated into the cigarette filter, either by application to the filter itself, or by encapsulation in a crushable pellet or capsule that releases volatile cooling agent into mainstream smoke when broken by finger pressure.
  • Many TRPV1 and/or TRPV3 agents, such as terpenoid compounds are volatile and therefore advantageous for delivery in the filter, entering mainstream smoke during its passage through the filter.
  • TRPV1 agents that may be included in the filter and/or capsule include Szechuan pepper, all spice, mustard and rosemary.
  • TRPV3 agents that may be included in the filter and/or capsule include camphor, carvacrol, thymol, and incensole acetate.
  • a cooling agent and a TRPV3 activating agent are combined in a pellet or capsule in the filter of a cigarette, while a TRPA1 agonist, including but not limited to aframomum malagueta extract (or 6-paradol) or a galangal extract or galangal acetate) is incorporated into tobacco and released into mainstream smoke during combustion.
  • a TRPA1 agonist including but not limited to aframomum malagueta extract (or 6-paradol) or a galangal extract or galangal acetate
  • a cooling agent and a TRPV1 activating agent are combined in a pellet or capsule in the filter of a cigarette, while a TRPA1 agonist, including but not limited to aframomum malagueta extract (or 6-paradol) or a galangal extract or galangal acetate) is incorporated into tobacco and released into mainstream smoke during combustion.
  • a TRPA1 agonist including but not limited to aframomum malagueta extract (or 6-paradol) or a galangal extract or galangal acetate
  • TRPV3 and TRPA1 activating agents may be more expensive and more volatile than TRPV1 activating agents. Therefore, inclusion of the TRPV3 and TRPA1 agents in a pellet or capsule offers advantages in using less of the agent (more cost effective) and improving the shelf life of the product.
  • Aframomum melegueta seeds 200 grams
  • powdered galangal root or ethanolic galangal extracts
  • the extract was filtered in three separate steps. Using a syringe and needle, 0.1 ml was injected into a light cigarette, withdrawing the needle while dispensing the extract from the syringe down the length of the tobacco column. After being allowed to dry, the cigarette displayed an intensified throat sensation, mimicking a key element of the sensory impact of a stronger cigarette.
  • Aframomum melegueta seeds (2.4 kg), thyme leaves (7.4 kg), rosemary (6.6 kg), and powdered galangal root (8.1 kg), were pulverized in a coffee grinder and extracted through a heated extraction process with 106 liters of methanol for 3 hours.
  • the extract was filtered in three separate steps. This extract was applied to tea leaves as a tobacco substitute. Application was by fine spray over the non-tobacco herbal cut-rag which was then mixed and tumbled to coat evenly.
  • the treated cut-rag was dried in a commercial grade oven for 4 hours. Following the drying process, the cut-rag was sprayed with propylene glycol to reach a moisture level of approximately 18%.
  • the non-tobacco herbal cut-rag was manufactured into cigarettes on a Hauni Protos high speed cigarette making line. The cigarettes displayed an intensified throat sensation, mimicking a key element of the sensory impact of a nicotine containing tobacco cigarette.
  • Aframomum melegueta seeds 200 grams
  • powdered galangal root, or ethanolic galangal extracts were pulverized in a coffee grinder and extracted through a heated extraction process with methanol for 3 hours.
  • the extract was filtered in three separate steps.
  • This extract was applied to a very low nicotine (VLN) tobacco cut-rag with less than 0.04% nicotine.
  • Application was by fine spray over the cut-rag which was then mixed and tumbled to coat evenly.
  • the treated cut-rag was dried in a commercial grade oven for 4 hours. Following the drying process, the cut-rag was sprayed with propylene glycol to reach a moisture level of approximately 18%.
  • the VLN cut-rag was hand-rolled into cigarettes, which displayed an intensified throat sensation, mimicking a key element of the sensory impact of a tobacco cigarette with regular level of nicotine content.
  • Aframomum melegueta seeds 200 grams
  • powdered galangal root, or ethanolic galangal extracts were pulverized in a coffee grinder and extracted through a heated extraction process with methanol for 3 hours.
  • the extract was filtered in three separate steps. This extract was applied to a blend of herb and tea leaves as a tobacco substitute. Application was by fine spray over the cut-rag which was then mixed and tumbled to coat evenly.
  • the treated cut-rag was dried in a commercial grade oven. Following the drying process, the cut-rag was cut and ground finely and sprayed with vegetable glycerin to reach a moisture level of approximately 18%.
  • the moist cut-rag was then placed into a herbal vaporizer device, which upon heating displayed an intensified throat sensation, mimicking a key element of the sensory impact of a tobacco vaporizer.
  • the composition of Example 4 is particularly advantageous for use in non-combustion heat not burn technology in which the composition is heated to release vapor or aerosol but burning and combustion is not required.
  • the device may be a heat stick, for example a shorter cigarette type device including a tobacco blend.
  • the device may also be a reusable device that accepts any type of cut rag or material in a heating chamber.
  • constituents are not limiting and the described constituents include equivalents such as synthetic alternatives. It will also be appreciated that description of constituents in compositions as by weight or by volume is merely exemplary and is not limiting. Constituents may be measured using any of a variety of available methods.
  • the above described devices and compositions are not limited to cigarette-like rods, but are also applicable to other devices such as inhalers that may be used to deliver the constituent(s). Also, it will be appreciated that the above described devices are applicable to applications beyond smoking substitution and smoking cessation.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Botany (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Cigarettes, Filters, And Manufacturing Of Filters (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (8)

  1. Vorrichtung (10) zum Nachahmen des Gefühls einer Inhalation von Tabakrauch, umfassend:
    eine Hülle (14);
    einen Tabakersatz (126), der in der Hülle (14) angeordnet ist; und
    einen ersten Extrakt, der ein Mittel enthält, das einen TRPA1-Kanal aktiviert;
    wobei das erste Mittel mindestens eines von Paradieskörnern (Aframomum melegueta), Galgant und 6-Paradol einschließt;
    einen zweiten Extrakt, der ein Mittel enthält, das sich von dem ersten Mittel unterscheidet und mindestens einen von einem TRPM8-Kanal, einem TRPV3-Kanal und einem TRPV1-Kanal aktiviert,
    wobei der erste Extrakt und der zweite Extrakt jeweils als ein Spray auf den Tabakersatz aufgetragen werden, um den Tabakersatz (126) zu überziehen, und der Tabakersatz dann getrocknet wird;
    wobei die Vorrichtung (10) flüchtige Verbindungen freisetzt, wenn sie auf eine Temperatur unterhalb eines Verbrennungspunkts des Tabakersatzes erhitzt wird.
  2. Vorrichtung nach Anspruch 1 wobei
    der Tabakersatz (126) aus Kräuter- und Teeblättern gebildet ist.
  3. Zusammensetzung zum Nachahmen des Gefühls einer Inhalation von Tabakrauch, umfassend:
    einen Tabakersatz (126);
    einen ersten Extrakt, der ein Mittel enthält, das einen TRPA1-Kanal aktiviert;
    wobei das erste Mittel mindestens eines von Paradieskörnern (Aframomum melegueta), Galgant und 6-Paradol einschließt; und
    einen zweiten Extrakt, der ein Mittel enthält, das sich von dem ersten Mittel unterscheidet und mindestens einen von einem TRPM8-Kanal, einem TRPV3-Kanal und einem TRPV1-Kanal aktiviert,
    wobei der erste Extrakt und der zweite Extrakt jeweils als ein Spray auf den Tabakersatz aufgetragen werden, um den Tabakersatz zu überziehen, und der Tabakersatz dann getrocknet wird;
    wobei die Zusammensetzung flüchtige Verbindungen freisetzt, wenn sie auf eine Temperatur unterhalb eines Verbrennungspunkts der Zusammensetzung erhitzt wird.
  4. Vorrichtung nach Anspruch 1, wobei die Vorrichtung zumindest teilweise verbrennbar ist.
  5. Vorrichtung nach Anspruch 1, weiter umfassend
    einen Filter, der zu einem Ende der Vorrichtung hin angeordnet ist und mit der Hülle verbunden ist.
  6. Vorrichtung nach Anspruch 1, wobei das
    zweite Mittel, das einen TRPM8-Kanal aktiviert, so bedienbar ist, dass es ein kühlendes Gefühl bereitstellt und
    optional oder vorzugsweise wobei das zweite Mittel mindestens eines von Menthol, Physcool (Monomenthylsuccinat), Icilin, Geraniol, Linalool, Hydroxycitronellal, WS-3, WS-23, PMD38, Cool-actP, FrescolatMGA, FrescolatMA und PMD38 einschließt.
  7. Vorrichtung nach Anspruch 1, wobei das
    zweite Mittel, das einen TRPV3-Kanal aktiviert, so bedienbar ist, dass es ein wärmendes Gefühl bereitstellt; und
    optional oder vorzugsweise wobei das zweite Mittel mindestens eines von Carvacrol, Thymol, Eugenol, Eukalyptol, Incensol, Borneol, Kampfer oder Dihydrocarveol einschließt.
  8. Vorrichtung nach Anspruch 1, wobei das zweite Mittel mindestens eines von Szechuan-Pfeffer, Piment, Senf und Rosmarin einschließt.
EP17854026.6A 2016-09-23 2017-09-22 Mittel zur modulation der sensorischen auswirkung von tabak- oder pflanzlichem rauch Active EP3515215B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662398875P 2016-09-23 2016-09-23
PCT/US2017/053052 WO2018057954A1 (en) 2016-09-23 2017-09-22 Agents and methods for modulating the sensory impact of tobacco or herbal smoke

Publications (3)

Publication Number Publication Date
EP3515215A1 EP3515215A1 (de) 2019-07-31
EP3515215A4 EP3515215A4 (de) 2020-09-09
EP3515215B1 true EP3515215B1 (de) 2025-06-11

Family

ID=61687788

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17854026.6A Active EP3515215B1 (de) 2016-09-23 2017-09-22 Mittel zur modulation der sensorischen auswirkung von tabak- oder pflanzlichem rauch

Country Status (6)

Country Link
US (1) US20180084827A1 (de)
EP (1) EP3515215B1 (de)
CN (1) CN109922676A (de)
CA (1) CA3037723A1 (de)
ES (1) ES3036472T3 (de)
WO (1) WO2018057954A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108936783B (zh) * 2018-09-17 2021-07-02 中烟施伟策（云南）再造烟叶有限公司 利用沸腾法制粒制备加热不燃烧卷烟用抽吸材料的方法
KR102892397B1 (ko) * 2022-12-30 2025-12-02 주식회사 케이티앤지 쿨링 블록을 포함하는 에어로졸 생성 물품용 캡슐, 및 이를 포함하는 에어로졸 생성 물품
WO2025224489A1 (en) * 2024-04-25 2025-10-30 Venerable Panadure Ananda Thero A formulation of herbal cigarette and its method of manufacturing thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135010A (en) * 1991-08-09 1992-08-04 Fan Sophie S M Herbal smoking materials

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1284151A (en) * 1969-08-18 1972-08-02 Int Flavors & Fragrances Inc Tobacco containing encapsulated flavor
US5383478A (en) * 1993-01-12 1995-01-24 Duke University Low tar and low nicotine cigarette adapted to provide enhanced smoking satisfaction
US10285431B2 (en) 2004-12-30 2019-05-14 Philip Morris Usa Inc. Encapsulated flavorant designed for thermal release and cigarette bearing the same
US7578298B2 (en) 2005-02-04 2009-08-25 Philip Morris Usa Inc. Flavor capsule for enhanced flavor delivery in cigarettes
CN101116534A (zh) * 2007-09-14 2008-02-06 谢兰银 能替代烟草的保健型固体烟棒
CN101263932A (zh) * 2008-04-30 2008-09-17 钱兆林 一种绿色香烟——茶烟
US20110104080A1 (en) * 2009-11-03 2011-05-05 David Salloum Salloum Oral Compositions for Treatment of Dry Mouth
EP3295794A1 (de) * 2010-07-27 2018-03-21 Flex Pharma, Inc. Verfahren und zusammensetzungen zur vorbeugung und linderung von muskelkrämpfen und zur erholung von neuromuskulärer reizbarkeit und erschöpfung nach dem training
US8646461B2 (en) * 2011-12-14 2014-02-11 Sentiens, Llc Device and method for simulating chemosensation of smoking
US10335378B2 (en) 2013-03-15 2019-07-02 Altria Client Services Llc Inhibition of central nervous system effects from smoking and sensory effects from smoking
JP2016532691A (ja) * 2013-08-02 2016-10-20 センティエンズ，エルエルシー 禁煙及び他の処置のための組成物及びそれらの使用
LU92296B1 (de) * 2013-10-18 2015-04-20 Valeo Lab Gmbh Fl}ssige Zusammensetzung f}r eine elektronische Zigarette
HK1225581B (en) * 2013-12-20 2017-09-15 Philip Morris Products S.A. Smoking article having a filter including a capsule
CN106537149A (zh) * 2014-04-01 2017-03-22 宝洁公司 用于筛选色氨酸通道的方法
CN104770858A (zh) * 2015-02-11 2015-07-15 贵州中烟工业有限责任公司 一种保护胃黏膜的口含型无烟气烟草制品及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135010A (en) * 1991-08-09 1992-08-04 Fan Sophie S M Herbal smoking materials

Also Published As

Publication number Publication date
CN109922676A (zh) 2019-06-21
WO2018057954A1 (en) 2018-03-29
ES3036472T3 (en) 2025-09-19
EP3515215A4 (de) 2020-09-09
CA3037723A1 (en) 2018-03-29
EP3515215A1 (de) 2019-07-31
US20180084827A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
EP2790536B1 (de) Vorrichtung und verfahren zur simulation der geruchs- und geschmackswahrnehmung des rauchens
EP3136895B1 (de) Inhalator für aromatisiertes nikotinpulver
RS58457B1 (sr) Zamena za duvan
EP3515215B1 (de) Mittel zur modulation der sensorischen auswirkung von tabak- oder pflanzlichem rauch
CN116157027A (zh) 阻燃材料及其用途
KR20220156075A (ko) 에어로졸 생성 구성요소들 및 이들을 준비하기 위한 방법
CN116113338A (zh) 具有阻燃特性的气溶胶生成材料及其用途
EP4681557A1 (de) Artikel zur verwendung mit einer vorrichtung zur bereitstellung eines nichtbrennbaren aerosols und system zur bereitstellung eines nichtbrennbaren aerosols
JP2026502624A (ja) エアロゾル生成材料
KR20250059535A (ko) 불연성 에어로졸 제공 시스템
WO2025242616A1 (en) Aerosol generating article and aerosol provision system
WO2025224489A1 (en) A formulation of herbal cigarette and its method of manufacturing thereof
WO2025196234A1 (en) Article for aerosol provision system and aerosol provision system
TW202432008A (zh) 氣溶膠產生材料
WO2025229310A1 (en) Control circuit, cartomizer for aerosol provision system and aerosol provision system
HK1229651A1 (en) Flavoured nicotine powder inhaler
HK1229651B (en) Flavoured nicotine powder inhaler

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190410

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A24B 15/16 20200101ALI20200421BHEP

Ipc: A24B 15/18 20060101ALI20200421BHEP

Ipc: A24B 15/30 20060101ALI20200421BHEP

Ipc: A24B 15/28 20060101AFI20200421BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20200811

RIC1 Information provided on ipc code assigned before grant

Ipc: A24B 15/30 20060101ALI20200805BHEP

Ipc: A24B 15/28 20060101AFI20200805BHEP

Ipc: A24B 15/16 20200101ALI20200805BHEP

Ipc: A24B 15/18 20060101ALI20200805BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210504

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A24B0015280000

Ipc: A24F0047000000

Ref document number: 602017089926

Country of ref document: DE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A24B 15/30 20060101ALI20241209BHEP

Ipc: A24B 15/28 20060101ALI20241209BHEP

Ipc: A24B 15/16 20060101ALI20241209BHEP

Ipc: A24F 47/00 20060101AFI20241209BHEP

INTG Intention to grant announced

Effective date: 20250102

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017089926

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 3036472

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20250919

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251001

REG Reference to a national code

Ref country code: CH

Ref legal event code: W10

Free format text: ST27 STATUS EVENT CODE: U-0-0-W10-W00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250611

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250926

Year of fee payment: 9

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250911

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250912

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20250922

Year of fee payment: 9

Ref country code: IT

Payment date: 20250926

Year of fee payment: 9

Ref country code: LU

Payment date: 20250925

Year of fee payment: 9

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20250611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250611

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250923

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250611

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250925

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250911

REG Reference to a national code

Ref country code: CH

Ref legal event code: R17

Free format text: ST27 STATUS EVENT CODE: U-0-0-R10-R17 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251024

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250611

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: 1SOURCEIT, LLC

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602017089926

Country of ref document: DE

Owner name: 1SOURCELT, LLC, CHARLOTTE, US

Free format text: FORMER OWNER: SENTIENS, LLC, CHARLOTTE, NC, US

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251013

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1801682

Country of ref document: AT

Kind code of ref document: T

Effective date: 20250611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250611

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250611

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: UPC_APP_0016249_3515215/2025

Effective date: 20251208

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20251218 AND 20251224

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20251001

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250611

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250611

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20251015

Year of fee payment: 9